A novel extracellular vesicle paradigm for the treatment of COVID-19 induced acute respiratory distress syndrome (ARDS)

Efficacy of mesenchymal stem cells (MSCs) for treatment of acute respiratory distress syndrome (ARDS) suggests bioactive bone marrow MSC extracellular vesicles (BM-MSC EVs) may be effective. A patient with severe COVID-19 associated ARDS who was presumed to expire was treated with a BM-MSC EV prepar...

Full description

Saved in:
Bibliographic Details
Published inRespiratory medicine case reports Vol. 51; p. 102087
Main Authors Osborn, Erik, Ransom, John T., Shulman, Anastasiya, Sengupta, Vikram, Choudhry, Mohammed, Hafiz, Ali, Gooden, Jacob, Lightner, Amy L.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 2024
Elsevier
Subjects
ARDS
Extracellular vesicle
Mesenchymal stem cell
MSC
Mesenchymal stem cell
EV
MSC
Extracellular vesicle
ARDS
Online AccessGet full text

Cover

More Information
Summary:Efficacy of mesenchymal stem cells (MSCs) for treatment of acute respiratory distress syndrome (ARDS) suggests bioactive bone marrow MSC extracellular vesicles (BM-MSC EVs) may be effective. A patient with severe COVID-19 associated ARDS who was presumed to expire was treated with a BM-MSC EV preparation (14 doses over two months) as a rescue treatment for refractory COVID ARDS. Near complete reversal of lung inflammation and fibrosis (per computed tomography), near complete restoration of mobility, hospital discharge (3 months) with resumption of normal activities of daily living (one year) and return to work occurred. No adverse events occurred despite repeated dosing of investigational product, highlighting safety of this potential therapy for ARDS.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2024.102087